పాలియేటివ్ కేర్ & మెడిసిన్

నైరూప్య

Fatigue Improvement after Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Apropos of a Case

Javier Munoz* and Philip Kuriakose

A 54-year-old male presented with shortness of breath and was diagnosed with pulmonary emboli. Laboratory studies revealed hemolytic anemia. Flow cytometry showed a prominent white blood cell clone without CD59 in 85% (NV 0-3.0) and red blood cells with 8.5% CD59 absence (NV 0-3.0) confirming a diagnosis of paroxysmal nocturnal hemoglobinuria. Eculizumab was started to decrease the possibility of a thrombotic recurrence, with incidentally, a marked subjective improvement of symptomatology, as fatigue, was seen. We reviewed current literature regarding the improvement in fatigue seen in patients with paroxysmal nocturnal hemoglobinuria treated with eculizumab.